We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Modern Methods Accurately Detect Cervical Cancer

By LabMedica International staff writers
Posted on 20 Aug 2014
Print article
The BD Viper LT System for fully automated, integrated molecular testing on a table top analyzer
The Viper LT System for fully automated, integrated molecular testing on a table top analyzer (Photo courtesy of BD DIAGNOSTIC SYSTEMS)
The newer Papanicolaou test (Pap tests) and human papilloma virus (HPV) screening more accurately identify precancerous cellular changes that potentially develop into cervical cancer.

Compared to a conventional Pap tests, the newer approved process has increased detection of a significant precancerous condition by more than 64%, by making the cervical cells easier to see as the new liquid-based Pap test produces better results for screening and detecting cervical cancer and its precursors.

A clinical trial is underway at the Jersey Shore University Medical Center (Jersey City, NJ, USA) to detect the strains of HPV that lead to cervical cancer. HPV is present in more than 99% of women who develop cervical cancer. Newer DNA-based technology has also proven to be up to 40% more accurate than traditional Pap tests. Patients will have cancer causing HPV strains tested from the liquid-based Pap specimen to determine if either one or both tests will improve cancer detection. In order to be eligible to participate, women must be at least 21 years of age or older and have not had a Pap test in the past four months or a hysterectomy.

The scientists are using an HPV screening test (BDS-USHPV) designed to be used with BD Viper LT system and the BD SurePath liquid-based Pap test (BD Diagnostic; Burlington, NC, USA). The American Cancer Society (Atlanta, GA, USA) predicts that this year in the USA, more than 12,100 women will be diagnosed with cervical cancer, and roughly 4,220 women will die of the disease. When treated early, the chances of effectively treating and curing cervical cancer increase dramatically.

Mark Martens, MD, the study leader, said, “After decades of women going to their doctor for annual Pap tests, the FDA, in a historic decision in April 2014, approved HPV testing as a replacement for the Pap test. Because of this new option for patients, more tests are now being developed to further expand the options for women and we are excited to be a part of this new, more accurate, more sensitive, and more comfortable method to prevent cancer in women. It’s a groundbreaking development that provides women in our community with access to the best cervical health screening available today.”

Related Links:

Jersey Shore University Medical Center
BD Diagnostic
American Cancer Society


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Hemoglobin Testing System
VARIANTnbs
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test runs on the cobas liat system (Photo courtesy of Roche)

Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes

The U.S. Centers for Disease Control and Prevention (CDC) has reported that respiratory diseases in the United States reached high levels during the recent autumn and winter seasons, with SARS-CoV-2 leading... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics